Showing 4881-4890 of 7936 results for "".
- TruInject Injector Training System Receives Approval of Its Patenthttps://practicaldermatology.com/news/20140613-truinject_injector_training_system_receives_approval_of_its_patent/2459207/One of the key patent applications of TruInject Medical Corporation has been allowed by the US Patent Office. The patent is expected to issue shortly. The patent is for a cosmetic and therapeutic injector training system and is one of many pate
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Two States Pass Laws Banning Indoor Tanning for Minorshttps://practicaldermatology.com/news/20140527-two_states_pass_laws_banning_indoor_tanning_for_minors/2459230/Minnesota and Louisiana have both recently passed legislation banning the use of indoor tanning facilities for those under 18 years of age. Both laws go into effect on August 1, 2014. Nine states in total have instituted bans on indoor tanning for minors, including Vermont, California, Illinois, Ore
- Michelson Diagnostics Commences New Study with Melanoma Institute of Australiahttps://practicaldermatology.com/news/20140520-michelson_diagnostics_commences_new_study_with_melanoma_institute_of_australia/2459234/The UK based medical device company Michelson Diagnostics has commenced a clinical study to investigate use of Optical Coherence Tomography (OCT) in diagnosing basal cell carcinoma in collaboration with the Melanoma Institute of
- iMatrix Launches New Web Marketing Services for Dermatologistshttps://practicaldermatology.com/news/20140520-imatrix_launches_new_web_marketing_services_for_dermatologists/2459235/iMatrix, division of Internet Brands, Inc. revealed new online marketing services for dermatologists, including marketing solutions, including professionally designed websites, social media management, video marketing, pay-per-click advertising, and a comprehensive SEO/SEM service called Dominato
- New Data Demonstrate Significant Long-term Improvement in Scarring using Neodyne Biosciences embrace® Advanced Scar Therapyhttps://practicaldermatology.com/news/20140519-new_data_demonstrate_significant_long-term_improvement_in_scarring_using_neodyne_biosciences_embrace_advanced_scar_therapy/2459236/Neodyne Biosciences reported a highly significant improvement in scarring for patients treated with embrace® Advanced Scar Therapy versus control at
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw
- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- Survey Finds Rosacea Sufferers' More Likely to be Judged Negatively Upon First Impressionhttps://practicaldermatology.com/news/20140428-survey_finds__rosacea_sufferers_more_likely_to_be_judged_negatively_upon_first_impression/2459251/A new survey by the National Rosacea Society finds that rosacea sufferers' are often judged negatively upon first impression. Shy, nervous, and stressed are the three words respondents used to describe their view of an individual with redness on their face, without knowing anything about them.